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In our country the prevalence of HIV-HBV co-infection in
young infected patients, between 1985-1990, transmitted
through nosocomial or vertical path is approximately 40%.
We followed the prevalence and risk factors associated
with liver damage in HIV+HBV infected patients. Longi-
tudinal evaluation of liver fibrosis was carried out in the
patients included in the study group, by transient elasto-
graphy (TE). Several studies using non-invasive methods
for the assessment of fibrosis have been performed in
HIV infected patients, and in patients co-infected with
hepatitis virus B, although up to now these methods
have not been validated for this segment of the popula-
tion. For statistical analysis, the TE results were desig-
nated to different stages of fibrosis in accordance with
the previous recommendations. The predefined cut-off
values were: F0-F1≤7.1 kPa, F2-F3>7.1 and ≤12.5 kPa
and for cirrhosis (corresponding to F4) >12.5kPa.
We included in the study 71 patients co-infected with
HIV and hepatitis B. 71.85% of patients had minimal liver
damage, 18.30% of them had moderate to severe fibrosis,
9.85% were F4. Patients were divided according to CD4
count into three groups: CD4 (0-200)/cmm, [200-500)/
cmm, and >500 cells/cmm. By applying the ANOVA test
we found significant differences between the 3 groups
(p=0.037<a=0.05, F=3.472) and reading the Bonferroni
table shows that there are significant differences between
the values of FibroScan only in patients coinfected with
HIV+HBV with CD4 appropriate intervals (0 - 200] and
(>500) [cells/cmm], p=0.033<a=0.05, confidence interval
(CI) 95% (0139, 4572). We didn`t find significant
differences regarding patients’ liver disease between groups
with HIV-RNA viral load <400 copies/mL compared to
those with levels >400 copies/mL. For assessing the role of
hepatitis virus B in liver disease severity in co-infected
patients, patients were divided into two groups: HBV-
DNA level≤ 2,000 IU/mL and >2,000 IU/mL. Since
p=0.006<a=0.05, there are significant differences between
the mean values of FibroScan in the two groups, HIV
+HBV patients with HBV-DNA (0-2,000 IU/mL and
>2,000 IU/mL), 95%CI (-4.642,-0.788).
We confirm the role of HIV-induced immunosuppres-
sion in liver disease progression. As well we confirm the
presence of more severe liver disease linked to hepatitis
virus B replication.
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